Literature DB >> 11005569

Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression.

S Aggarwal1, N Taneja, L Lin, M B Orringer, A Rehemtulla, D G Beer.   

Abstract

The prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been shown to exert a chemopreventive effect in esophageal and other gastrointestinal tumors. The precise mechanism by which this occurs, however, is unknown. While the inhibition of COX-2 as a potential explanation for this chemopreventive effect has gained a great deal of support, there also exists evidence supporting the presence of cyclooxygenase-independent pathways through which NSAIDs may exert their effects. In this study, immunohistochemical analysis of 29 Barrett's epithelial samples and 60 esophageal adenocarcinomas demonstrated abundant expression of the COX-2 protein in Barrett's epithelium, but marked heterogeneity of expression in esophageal adenocarcinomas. The three esophageal adenocarcinoma cell lines, Flo-1, Bic-1, and Seg-1, also demonstrated varying expression patterns for COX-1 and COX-2. Indomethacin induced apoptosis in all three cell lines, however, in both a time- and dose-dependent manner. In Flo-1 cells, which expressed almost undetectable levels of COX-1 and COX-2, and in Seg-1, which expressed significant levels of COX-1 and COX-2, indomethacin caused upregulation of the pro-apoptotic protein Bax. The upregulation of Bax was accompanied by the translocation of mitochondrial cytochrome c to the cytoplasm, and activation of caspase 9. Pre-treatment of both cell lines with the specific caspase 9 inhibitor, z-LEHD-FMK, as well as the broad-spectrum caspase inhibitor, z-VAD-FMK, blocked the effect of indomethacin-induced apoptosis. These data demonstrate that induction of apoptosis by indomethacin in esophageal adenocarcinoma cells is associated with the upregulation of Bax expression and mitochondrial cytochrome c translocation, and does not correlate with the expression of COX-2. This may have important implications for identifying new therapeutic targets in this deadly disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005569      PMCID: PMC1550298          DOI: 10.1038/sj.neo.7900097

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  39 in total

Review 1.  NSAID use and decreased risk of gastrointestinal cancers.

Authors:  M J Thun
Journal:  Gastroenterol Clin North Am       Date:  1996-06       Impact factor: 3.806

Review 2.  Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract.

Authors:  J L Masferrer; P C Isakson; K Seibert
Journal:  Gastroenterol Clin North Am       Date:  1996-06       Impact factor: 3.806

3.  Sulindac suppresses tumorigenesis in the Min mouse.

Authors:  Y Beazer-Barclay; D B Levy; A R Moser; W F Dove; S R Hamilton; B Vogelstein; K W Kinzler
Journal:  Carcinogenesis       Date:  1996-08       Impact factor: 4.944

4.  Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).

Authors:  M Oshima; J E Dinchuk; S L Kargman; H Oshima; B Hancock; E Kwong; J M Trzaskos; J F Evans; M M Taketo
Journal:  Cell       Date:  1996-11-29       Impact factor: 41.582

5.  Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts.

Authors:  X Lu; W Xie; D Reed; W S Bradshaw; D L Simmons
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

6.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer.

Authors:  H Sano; Y Kawahito; R L Wilder; A Hashiramoto; S Mukai; K Asai; S Kimura; H Kato; M Kondo; T Hla
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

7.  Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis.

Authors:  B S Reddy; C V Rao; K Seibert
Journal:  Cancer Res       Date:  1996-10-15       Impact factor: 12.701

8.  Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2.

Authors:  M Tsujii; R N DuBois
Journal:  Cell       Date:  1995-11-03       Impact factor: 41.582

9.  Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis.

Authors:  G A Piazza; A L Rahm; M Krutzsch; G Sperl; N S Paranka; P H Gross; K Brendel; R W Burt; D S Alberts; R Pamukcu
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

10.  Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent.

Authors:  C V Rao; A Rivenson; B Simi; E Zang; G Kelloff; V Steele; B S Reddy
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

View more
  23 in total

1.  Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.

Authors:  Masood A Shammas; Aamer Qazi; Ramesh B Batchu; Robert C Bertheau; Jason Y Y Wong; Manjula Y Rao; Madhu Prasad; Diptiman Chanda; Selvarangan Ponnazhagan; Kenneth C Anderson; Christopher P Steffes; Nikhil C Munshi; Immaculata De Vivo; David G Beer; Sergei Gryaznov; Donald W Weaver; Raj K Goyal
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

2.  Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells.

Authors:  Xue Yang; Jee Hoon Song; Yulan Cheng; Wenjing Wu; Tushar Bhagat; Yiting Yu; John M Abraham; Sariat Ibrahim; William Ravich; Bani Chander Roland; Mouen Khashab; Vikesh K Singh; Eun Ji Shin; Xiao Yang; Amit K Verma; Stephen J Meltzer; Yuriko Mori
Journal:  Gut       Date:  2013-09-02       Impact factor: 23.059

Review 3.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

Review 4.  Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus.

Authors:  Panagiotis Tsibouris; Erasmia Vlachou; Peter Edward Thomas Isaacs
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

5.  Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth.

Authors:  Jagannath Pal; Mariateresa Fulciniti; Puru Nanjappa; Leutz Buon; Yu-Tzu Tai; Pierfrancesco Tassone; Nikhil C Munshi; Masood A Shammas
Journal:  Cancer Genomics Proteomics       Date:  2012 Mar-Apr       Impact factor: 4.069

6.  9-phenyl acridine exhibits antitumour activity by inducing apoptosis in A375 cells.

Authors:  Rita Ghosh; Sudipta Bhowmik; Dipanjan Guha
Journal:  Mol Cell Biochem       Date:  2011-10-01       Impact factor: 3.396

7.  Aspirin induces apoptosis through release of cytochrome c from mitochondria.

Authors:  K C Zimmermann; N J Waterhouse; J C Goldstein; M Schuler; D R Green
Journal:  Neoplasia       Date:  2000 Nov-Dec       Impact factor: 5.715

8.  Anticancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy.

Authors:  Aamer Qazi; Jagannath Pal; Ma'in Maitah; Mariateresa Fulciniti; Dheeraj Pelluru; Puru Nanjappa; Saem Lee; Ramesh B Batchu; Madhu Prasad; Christopher S Bryant; Samiyah Rajput; Sergei Gryaznov; David G Beer; Donald W Weaver; Nikhil C Munshi; Raj K Goyal; Masood A Shammas
Journal:  Transl Oncol       Date:  2010-12-01       Impact factor: 4.243

9.  Enhancement of 5-fluorouracil efficacy on high COX-2 expressing HCA-7 cells by low dose indomethacin and NS-398 but not on low COX-2 expressing HT-29 cells.

Authors:  Andrea Réti; Gábor Barna; Eva Pap; Vilmos Adleff; Viktor L Komlósi; András Jeney; Judit Kralovánszky; Barna Budai
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

Review 10.  Review of the molecular profile and modern prognostic markers for gastric lymphoma: how do they affect clinical practice?

Authors:  Leonidas Alevizos; Ilias P Gomatos; Spyridon Smparounis; Manousos M Konstadoulakis; Georgios Zografos
Journal:  Can J Surg       Date:  2012-04       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.